MicroRNA 1281 (miR-1281)

**MicroRNA 1281 (miR-1281)** is a short, non-coding RNA molecule (20–24 nucleotides) involved in regulating gene expression post-transcriptionally by binding to messenger RNAs (mRNAs) and modulating their stability or translation efficiency[2]. It is transcribed as part of a longer precursor and processed by the Drosha and Dicer enzymes to form the mature miRNA, which then associates with the RISC complex to guide gene silencing[2]. miR-1281 has been shown to be significantly upregulated in certain diseases, with strong evidence for its role as a sensitive and specific biomarker in **diabetic retinopathy**[1]. It is upregulated in high-glucose conditions in retinal epithelial cells, and extracellular miR-1281 promotes increased expression of the **VEGFA** gene in endothelial cells—a factor important in angiogenesis and retinal vascular pathology in diabetes[1]. Target prediction and mechanistic studies suggest a possible link between miR-1281, VEGFA, and hypoxia-inducible pathways, although direct therapeutic targeting is still under investigation[1]. Diseases associated with altered miR-1281 expression include not only diabetic retinopathy but also abdominal aortic aneurysm, coronary heart disease, pulmonary arterial hypertension, chronic kidney disease, immune thrombocytopenic purpura, and several cancers[1][2][3]. Its main biological functions derive from its general role as a microRNA: regulating cell differentiation, proliferation, apoptosis, and migration, especially as these processes relate to vascular and tissue pathophysiology[3]. Currently, no direct drug-targeting therapies or safety concerns have been described for miR-1281, but it is regarded as a promising circulating disease biomarker[1][2][3].

Other names

hsa-mir-1281MIR1281MIRN1281